StockNews.AI
NBIX
StockNews.AI
194 days

Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025

1. INGREZZA sales grew 23% in Q4 2024, indicating strong demand. 2. Guidance for 2025 anticipates $2.5-$2.6 billion in sales, signaling bullish growth.

Earnings
-18.94%Current Return
VS
-1.01%S&P 500
$150.5102/06 04:03 PM EDTEvent Start
$12202/07 10:35 PM EDTLatest Updated
2m saved
Insight
Article

FAQ

Why Very Bullish?

Steady growth and solid future guidance often boost investor confidence, as seen in other biotech firms post-strong earnings reports.

How important is it?

Strong sales and new product approvals are crucial for NBIX's market position and future potential.

Why Long Term?

Sustained sales growth and product approval suggest a long-term positive trend, like other successful biotech companies with consistent revenue increases.

Related Companies

NBIXNBI-568
INGREZZA® (valbenazine) Fourth Quarter and Full Year 2024 Net Product Sales of $615 Million and $2.3 Billion, Representing Year-Over-Year Growth of 23% and 26% Respectively INGREZZA® (valbenazine) Full Year 2025 Net Product Sales Guidance of $2.5 - $2.6 Billion CRENESSITYTM (crinecerfont), a First-in-Class Treatment for Children and Adults with Classic Congenital Adrenal Hyperplasia, Approved and Launched in the United States Phase 3 Programs for Osavampator in Major Depressive Disorder and NBI-'568 in Schizophrenia Initiating in the First Half of 2025 SAN DIEGO , Feb. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and full year ended December 31, 2024 and provided financial guidance for 2025. "I'm proud of the tremendous progress we made last year with the continued growth of INGREZZA for patients living with tardive dyskinesia or Huntington disease chorea.

Related News